Cargando…

Efficacy and safety of reperfusion treatments in middle-old and oldest-old stroke patients

INTRODUCTION: Intravenous thrombolysis (IT) and mechanical thrombectomy (MT) have significantly changed the clinical outcome of acute ischaemic stroke (AIS). Concerns about possible complications often reduce the use of these treatment options for older patients, preferentially managed with antiplat...

Descripción completa

Detalles Bibliográficos
Autores principales: Viticchi, Giovanna, Potente, Eleonora, Falsetti, Lorenzo, Burattini, Marco, Bartolini, Marco, Buratti, Laura, Pelliccioni, Giuseppe, Silvestrini, Mauro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213290/
https://www.ncbi.nlm.nih.gov/pubmed/35211810
http://dx.doi.org/10.1007/s10072-022-05958-4
_version_ 1784730809337380864
author Viticchi, Giovanna
Potente, Eleonora
Falsetti, Lorenzo
Burattini, Marco
Bartolini, Marco
Buratti, Laura
Pelliccioni, Giuseppe
Silvestrini, Mauro
author_facet Viticchi, Giovanna
Potente, Eleonora
Falsetti, Lorenzo
Burattini, Marco
Bartolini, Marco
Buratti, Laura
Pelliccioni, Giuseppe
Silvestrini, Mauro
author_sort Viticchi, Giovanna
collection PubMed
description INTRODUCTION: Intravenous thrombolysis (IT) and mechanical thrombectomy (MT) have significantly changed the clinical outcome of acute ischaemic stroke (AIS). Concerns about possible complications often reduce the use of these treatment options for older patients, preferentially managed with antiplatelet therapy (AT). Aim of this study was to evaluate, in a population of middle-old (75–84 years) and oldest-old (≥ 85 years) subjects, the efficacy and safety of different treatments for AIS (IT, IT + MT, MT or AT), mortality and incidence of serious complications. PATIENTS AND METHODS: All patients aged over 75 years admitted for AIS in two Stroke Units were enrolled. The physician in each case considered all treatment options and chose the best approach. NIHSS and modified Rankin Scale (mRS) were obtained and differences between admission and discharge scores, defined as delta(NIHSS) and delta(mRS), were calculated. The relationship between delta(NIHSS), delta(mRS) and type of procedure was analysed with a GLM/Multivariate model. Differences in mortality and incidence of serious complications were analysed with the chi-square test. RESULTS: A total of 273 patients, mean age 84.07 (± 5.47) years, were included. The Delta(NIHSS) was significantly lower in patients treated with AT than in those treated with IT and MT (p < 0.009 and p < 0.005, respectively). Haemorrhagic infarction occurrence was significantly lower (p < 0.0001) among patients treated with AT (10.6%) or IT (16.7%) compared to MT (34.9%) or MT + IT (37.0%). No significant difference was observed for in-hospital mortality. Age did not influence the outcome. CONCLUSIONS: Our results suggest that IT and AT are effective and relatively safe approaches in middle-aged and older patients.
format Online
Article
Text
id pubmed-9213290
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-92132902022-06-23 Efficacy and safety of reperfusion treatments in middle-old and oldest-old stroke patients Viticchi, Giovanna Potente, Eleonora Falsetti, Lorenzo Burattini, Marco Bartolini, Marco Buratti, Laura Pelliccioni, Giuseppe Silvestrini, Mauro Neurol Sci Original Article INTRODUCTION: Intravenous thrombolysis (IT) and mechanical thrombectomy (MT) have significantly changed the clinical outcome of acute ischaemic stroke (AIS). Concerns about possible complications often reduce the use of these treatment options for older patients, preferentially managed with antiplatelet therapy (AT). Aim of this study was to evaluate, in a population of middle-old (75–84 years) and oldest-old (≥ 85 years) subjects, the efficacy and safety of different treatments for AIS (IT, IT + MT, MT or AT), mortality and incidence of serious complications. PATIENTS AND METHODS: All patients aged over 75 years admitted for AIS in two Stroke Units were enrolled. The physician in each case considered all treatment options and chose the best approach. NIHSS and modified Rankin Scale (mRS) were obtained and differences between admission and discharge scores, defined as delta(NIHSS) and delta(mRS), were calculated. The relationship between delta(NIHSS), delta(mRS) and type of procedure was analysed with a GLM/Multivariate model. Differences in mortality and incidence of serious complications were analysed with the chi-square test. RESULTS: A total of 273 patients, mean age 84.07 (± 5.47) years, were included. The Delta(NIHSS) was significantly lower in patients treated with AT than in those treated with IT and MT (p < 0.009 and p < 0.005, respectively). Haemorrhagic infarction occurrence was significantly lower (p < 0.0001) among patients treated with AT (10.6%) or IT (16.7%) compared to MT (34.9%) or MT + IT (37.0%). No significant difference was observed for in-hospital mortality. Age did not influence the outcome. CONCLUSIONS: Our results suggest that IT and AT are effective and relatively safe approaches in middle-aged and older patients. Springer International Publishing 2022-02-24 2022 /pmc/articles/PMC9213290/ /pubmed/35211810 http://dx.doi.org/10.1007/s10072-022-05958-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Viticchi, Giovanna
Potente, Eleonora
Falsetti, Lorenzo
Burattini, Marco
Bartolini, Marco
Buratti, Laura
Pelliccioni, Giuseppe
Silvestrini, Mauro
Efficacy and safety of reperfusion treatments in middle-old and oldest-old stroke patients
title Efficacy and safety of reperfusion treatments in middle-old and oldest-old stroke patients
title_full Efficacy and safety of reperfusion treatments in middle-old and oldest-old stroke patients
title_fullStr Efficacy and safety of reperfusion treatments in middle-old and oldest-old stroke patients
title_full_unstemmed Efficacy and safety of reperfusion treatments in middle-old and oldest-old stroke patients
title_short Efficacy and safety of reperfusion treatments in middle-old and oldest-old stroke patients
title_sort efficacy and safety of reperfusion treatments in middle-old and oldest-old stroke patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213290/
https://www.ncbi.nlm.nih.gov/pubmed/35211810
http://dx.doi.org/10.1007/s10072-022-05958-4
work_keys_str_mv AT viticchigiovanna efficacyandsafetyofreperfusiontreatmentsinmiddleoldandoldestoldstrokepatients
AT potenteeleonora efficacyandsafetyofreperfusiontreatmentsinmiddleoldandoldestoldstrokepatients
AT falsettilorenzo efficacyandsafetyofreperfusiontreatmentsinmiddleoldandoldestoldstrokepatients
AT burattinimarco efficacyandsafetyofreperfusiontreatmentsinmiddleoldandoldestoldstrokepatients
AT bartolinimarco efficacyandsafetyofreperfusiontreatmentsinmiddleoldandoldestoldstrokepatients
AT burattilaura efficacyandsafetyofreperfusiontreatmentsinmiddleoldandoldestoldstrokepatients
AT pelliccionigiuseppe efficacyandsafetyofreperfusiontreatmentsinmiddleoldandoldestoldstrokepatients
AT silvestrinimauro efficacyandsafetyofreperfusiontreatmentsinmiddleoldandoldestoldstrokepatients